This finding aligns with previous studies that have deciphered the effect of tocilizumab (an IL-6 inhibitor) on restoring zebrafish swimming ability impaired by the administration of CML [32]. This evidence concerns the gene IL6 and chronic myelogenous leukemia, BCR-ABL1 positive.